Giredestrant Plus Everolimus Just Cleared the Bar: What the evERA Data Actually Demands From Trial Designers

Giredestrant Plus Everolimus Just Cleared the Bar: What the evERA Data Actually Demands From Trial Designers

The VIRAGE Trial Cracked the Pancreatic Cancer Wall. Now the Hard Question Is Whether the Field Can Read the Blueprint.

The VIRAGE Trial Cracked the Pancreatic Cancer Wall. Now the Hard Question Is Whether the Field Can Read the Blueprint.

The Brain-Wave Trial That Just Raised the Bar for Neuromodulation RCTs

The Brain-Wave Trial That Just Raised the Bar for Neuromodulation RCTs

AB Science's "Calendar Update" Is a GCP Inspection Disclosure in Disguise

AB Science’s “Calendar Update” Is a GCP Inspection Disclosure in Disguise

Editor's Choice

Your IP Is Sitting in a Freezer Somewhere, And Your CRA Doesn't Know Where
Clinical Trial Ops Brief

Your IP Is Sitting in a Freezer Somewhere, And Your CRA Doesn’t Know Where

Enrollment Closed: What Moleculin's MIRACLE Trial Teaches About AML Site Execution
Clinical Trial Ops Brief

Enrollment Closed: What Moleculin’s MIRACLE Trial Teaches About AML Site Execution

When the Primary Endpoint Moves After 283 Patients Are Already In
Clinical Trial Ops Brief

When the Primary Endpoint Moves After 283 Patients Are Already In

CLINICAST

Start typing and press Enter to search